ABG Acquisition Corp. I announced the pricing of its upsized $131 million IPO this morning and its shares are expected to begin trading on the Nasdaq under the symbol “ABGI,” Wednesday, February 17.
The new company aims to combine with a healthcare business that is potentially disruptive or possessing a drug candidate offering differentiated therapies. ABG I is led by CEO Fan Yu and CFO Daniel Johnson.
Total SPAC deal count for 2021 year-to-date is now 49. This offering is expected to close on Friday, February 19.
Jefferies LLC is acting as the sole book-running manager for the offering. Kirkland & Ellis LLP is serving as Issuer’s Counsel with White & Case LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.